Lysosomal membrane localization of organic anion transporting polypeptide 2B1 in human hepatocytes.

IF 3.6 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Yeseul Ahn, Jacqueline B Tiley, Bhagwat Prasad, Kim L R Brouwer
{"title":"Lysosomal membrane localization of organic anion transporting polypeptide 2B1 in human hepatocytes.","authors":"Yeseul Ahn, Jacqueline B Tiley, Bhagwat Prasad, Kim L R Brouwer","doi":"10.1016/j.dmd.2026.100386","DOIUrl":null,"url":null,"abstract":"<p><p>Organic anion transporting polypeptide 2B1 (OATP2B1) is a basolateral plasma membrane uptake transporter expressed in hepatocytes. However, the cellular internalization and degradation pathways of OATP2B1 remain poorly characterized. Filling this knowledge gap is critical for improving predictions of OATP2B1 substrate disposition and OATP2B1-mediated drug interactions. This study investigated the localization and primary degradation pathway of OATP2B1 in human hepatocytes and examined whether OATP2B1 localization was affected by metabolic dysfunction-associated steatohepatitis in human liver tissue. Sandwich-cultured human hepatocytes (SCHHs) were treated with either 25 μM chloroquine (CQ) or 10 μM MG-132 to inhibit lysosomal or proteasomal degradation, respectively. Following treatment, SCHHs were fixed and stained for OATP2B1 and lysosome-associated membrane protein (LAMP) 1, followed by confocal imaging and subsequent object-based quantitative analysis. Lysosomal inhibition by CQ in SCHHs resulted in significant accumulation of intracellular OATP2B1, which displayed major colocalization with the lysosomal marker, LAMP1 (20% ± 9.38% vs 9.5% ± 5.25%; CQ vs control, respectively; P < .0001). In contrast, the OATP2B1 total object volume and intracellular localization remained unchanged after MG-132 treatment. OATP2B1 colocalization with LAMP1 was significantly higher in liver tissue from patients with metabolic dysfunction-associated steatohepatitis (10.47% ± 4.95%) compared with control liver tissue (6.00% ± 2.06%; P < .0001). Super-resolution imaging using stimulated emission depletion microscopy revealed that OATP2B1 was localized on lysosomal membranes. In conclusion, these findings demonstrate that OATP2B1 degrades primarily via lysosomes in human hepatocytes. Lysosomal dysfunction associated with some xenobiotics or disease may increase OATP2B1 localization on lysosomal membranes. SIGNIFICANCE STATEMENT: This study confirms that lysosomes are the predominant degradation pathway for the basolateral membrane protein organic anion transporting polypeptide 2B1 (OATP2B1) in human hepatocytes. Super-resolution imaging revealed that OATP2B1 is localized on lysosomal membranes. Both lysosomal inhibition by chloroquine in vitro and lysosomal dysfunction associated with metabolic dysfunction-associated steatohepatitis in human liver tissue increased OATP2B1 colocalization with the lysosomal membrane marker.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":"54 10","pages":"100386"},"PeriodicalIF":3.6000,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism and Disposition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.dmd.2026.100386","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Organic anion transporting polypeptide 2B1 (OATP2B1) is a basolateral plasma membrane uptake transporter expressed in hepatocytes. However, the cellular internalization and degradation pathways of OATP2B1 remain poorly characterized. Filling this knowledge gap is critical for improving predictions of OATP2B1 substrate disposition and OATP2B1-mediated drug interactions. This study investigated the localization and primary degradation pathway of OATP2B1 in human hepatocytes and examined whether OATP2B1 localization was affected by metabolic dysfunction-associated steatohepatitis in human liver tissue. Sandwich-cultured human hepatocytes (SCHHs) were treated with either 25 μM chloroquine (CQ) or 10 μM MG-132 to inhibit lysosomal or proteasomal degradation, respectively. Following treatment, SCHHs were fixed and stained for OATP2B1 and lysosome-associated membrane protein (LAMP) 1, followed by confocal imaging and subsequent object-based quantitative analysis. Lysosomal inhibition by CQ in SCHHs resulted in significant accumulation of intracellular OATP2B1, which displayed major colocalization with the lysosomal marker, LAMP1 (20% ± 9.38% vs 9.5% ± 5.25%; CQ vs control, respectively; P < .0001). In contrast, the OATP2B1 total object volume and intracellular localization remained unchanged after MG-132 treatment. OATP2B1 colocalization with LAMP1 was significantly higher in liver tissue from patients with metabolic dysfunction-associated steatohepatitis (10.47% ± 4.95%) compared with control liver tissue (6.00% ± 2.06%; P < .0001). Super-resolution imaging using stimulated emission depletion microscopy revealed that OATP2B1 was localized on lysosomal membranes. In conclusion, these findings demonstrate that OATP2B1 degrades primarily via lysosomes in human hepatocytes. Lysosomal dysfunction associated with some xenobiotics or disease may increase OATP2B1 localization on lysosomal membranes. SIGNIFICANCE STATEMENT: This study confirms that lysosomes are the predominant degradation pathway for the basolateral membrane protein organic anion transporting polypeptide 2B1 (OATP2B1) in human hepatocytes. Super-resolution imaging revealed that OATP2B1 is localized on lysosomal membranes. Both lysosomal inhibition by chloroquine in vitro and lysosomal dysfunction associated with metabolic dysfunction-associated steatohepatitis in human liver tissue increased OATP2B1 colocalization with the lysosomal membrane marker.

人肝细胞有机阴离子转运多肽2B1的溶酶体膜定位。
有机阴离子转运多肽2B1 (OATP2B1)是一种在肝细胞中表达的基侧质膜摄取转运蛋白。然而,OATP2B1的细胞内化和降解途径仍然不清楚。填补这一知识空白对于改善对OATP2B1底物处置和OATP2B1介导的药物相互作用的预测至关重要。本研究研究了OATP2B1在人肝细胞中的定位和初级降解途径,并探讨了OATP2B1的定位是否受到人肝组织代谢功能障碍相关性脂肪性肝炎的影响。用25 μM氯喹(CQ)或10 μM MG-132分别抑制三明治培养的人肝细胞(SCHHs)的溶酶体或蛋白酶体降解。治疗后,对schh进行固定,并对OATP2B1和溶酶体相关膜蛋白(LAMP) 1进行染色,然后进行共聚焦成像和随后的基于物体的定量分析。CQ抑制SCHHs溶酶体导致细胞内OATP2B1显著积累,与溶酶体标志物LAMP1共定位(分别为20%±9.38% vs 9.5%±5.25%;CQ vs对照组;P < 0.0001)。相比之下,MG-132处理后,OATP2B1的总靶体积和细胞内定位保持不变。代谢功能障碍相关脂肪性肝炎患者肝组织中OATP2B1与LAMP1共定位(10.47%±4.95%)明显高于对照肝组织(6.00%±2.06%;P < 0.0001)。利用受激发射耗尽显微镜的超分辨率成像显示OATP2B1定位在溶酶体膜上。总之,这些发现表明OATP2B1主要通过人肝细胞中的溶酶体降解。溶酶体功能障碍与某些外源性药物或疾病相关,可增加OATP2B1在溶酶体膜上的定位。意义声明:本研究证实溶酶体是人肝细胞基底外侧膜蛋白有机阴离子转运多肽2B1 (OATP2B1)的主要降解途径。超分辨率成像显示OATP2B1定位于溶酶体膜上。体外氯喹溶酶体抑制和人肝组织代谢功能障碍相关脂肪性肝炎溶酶体功能障碍均增加OATP2B1与溶酶体膜标记物的共定位。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.50
自引率
12.80%
发文量
128
审稿时长
3 months
期刊介绍: An important reference for all pharmacology and toxicology departments, DMD is also a valuable resource for medicinal chemists involved in drug design and biochemists with an interest in drug metabolism, expression of drug metabolizing enzymes, and regulation of drug metabolizing enzyme gene expression. Articles provide experimental results from in vitro and in vivo systems that bring you significant and original information on metabolism and disposition of endogenous and exogenous compounds, including pharmacologic agents and environmental chemicals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书